Evidence map›Paper›PMID 42072720›Full record

ArticleBiomolecules2026

Fragment-Derived Nicotinic Acid Analogues Inhibit hCA III and Downregulate

Areej Abuhammad, Tamara Sabri, Nidaa A Ababneh, Rya A Ali, Mohammad A Ismail, Adan Madadha, Dareen T Yazjeen, Rama J Alghanem, Ali M Qaisi, Yusuf Al-Hiari and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Areej AbuhammadDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0003-4978-5059
Tamara SabriDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
Nidaa A AbabnehCell Therapy Center, The University of Jordan, Amman 11942, Jordan.
Rya A AliDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
Mohammad A IsmailCell Therapy Center, The University of Jordan, Amman 11942, Jordan.ORCID 0000-0001-5039-8764
Adan MadadhaCell Therapy Center, The University of Jordan, Amman 11942, Jordan.
Dareen T YazjeenDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
Rama J AlghanemDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
Ali M QaisiDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
Yusuf Al-HiariDepartment of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman 11942, Jordan.
Kapil GuptaSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.
Imre BergerSchool of Biochemistry, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0001-7518-9045
Edith SimDepartment of Pharmacology, University of Oxford, Oxford OX1 3QT, UK.

Funding

Deanship of Scientific Research at the University of Jordan 2214Deanship of Scientific Research at the University of Jordan 2283Scientific Research Fund of the Ministry of Higher Education MPH2192014
6 · The paper itself

Abstract

Chronic oxidative stress and lipid imbalance drive metabolic disorders such as obesity and non-alcoholic fatty liver disease, yet few therapies target the upstream redox imbalance in key tissues. Human carbonic anhydrase III (hCA III), a redox-associated enzyme enriched in liver and adipose tissue, has long remained pharmacologically elusive due to its low catalytic activity and lack of modulators. Here, we identify fragment-like nicotinic acid derivatives as non-sulfonamide hCA III modulators and evaluate their associated cellular effects. Using an esterase activity assay, we screened 25 analogues and identified two fragment-like hits, compound

Indexed as

Carbonic Anhydrase IIIDown-RegulationNiacinNicotinic AcidsHep G2 CellsHumansMembrane Potential, MitochondrialOxidative StressCarbonic Anhydrase IIINiacinNicotinic Acidscarbonic anhydrase IIIfragment-based drug discoverygene expression modulationmetabolic diseasenicotinic acid derivativesoxidative stress

Identifiers

PMID42072720
PMCPMC13113631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.